Skip to main content
. 2021 Apr;9(8):652. doi: 10.21037/atm-20-7037

Figure 1.

Figure 1

Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). (A) PFS and OS of overall patient cohort. (B) Comparison of PFS between patients receiving the combination therapy as the first line treatment and those as the second to fourth line. (C) Comparison of PFS between patients receiving sintilimab plus TKIs synchronously and those receiving sintilimab after TKIs.